Similar articles

• Clinical potential of low molecular weight heparins.

  Messmore HL Jr. Messmore HL Jr. Semin Thromb Hemost. 1989 Oct;15(4):405-8. doi: 10.1055/s-2007-1002739. Semin Thromb Hemost. 1989. PMID: 2554501 Review. No abstract available.
• [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2003 Jun 12;145(24):56. MMW Fortschr Med. 2003. PMID: 12866309 German. No abstract available.
• Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.

  Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Watanabe M, Mochizuki H. Takahashi Y, et al. Thromb Haemost. 1997 Apr;77(4):789-95. Thromb Haemost. 1997. PMID: 9134660
• Clinical use of low molecular weight heparins and heparinoids.

  Levine MN, Hirsh J. Levine MN, et al. Semin Thromb Hemost. 1988 Jan;14(1):116-25. doi: 10.1055/s-2007-1002764. Semin Thromb Hemost. 1988. PMID: 2451292 Review. No abstract available.
• Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.

  Kakkar VV. Kakkar VV. Semin Hematol. 1997 Oct;34(4 Suppl 4):9-19. Semin Hematol. 1997. PMID: 9399405 Review. No abstract available.